Загрузка...
Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility
Baloxavir marboxil (BXM) was approved in 2018 for treating influenza A and B virus infections. It is a first-in-class inhibitor targeting the endonuclease activity of the virus polymerase acidic (PA) protein. Clinical trial data revealed that PA amino acid substitutions at residue 38 (I38T/F/M) redu...
Сохранить в:
| Опубликовано в: : | Proc Natl Acad Sci U S A |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
National Academy of Sciences
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7165484/ https://ncbi.nlm.nih.gov/pubmed/32217734 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1916825117 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|